Proteomics and metabolomics in inflammatory bowel disease

J Gastroenterol Hepatol. 2013 Jul;28(7):1076-86. doi: 10.1111/jgh.12193.


Genome-wide studies in inflammatory bowel disease (IBD) have allowed us to understand Crohn's disease and ulcerative colitis as forms of related autoinflammatory disorders that arise from a multitude of pathogenic origins. Proteomics and metabolomics are the offspring of genomics that possess unprecedented possibilities to characterize unknown pathogenic pathways. It has been about a decade since proteomics was first applied to IBD, and 5 years for metabolomics. These techniques have yielded novel and potentially important findings, but turning these results into beneficial patient outcomes remains challenging. This review recounts the history and context of clinical IBD developments before and after proteomics and metabolomics IBD in this field, discusses the challenges in consolidating high complexity data with physiological understanding, and provides an outlook on the emerging principles that will help interface the bioanalytical laboratory with IBD prognosis.

Publication types

  • Review

MeSH terms

  • Environmental Exposure / adverse effects
  • Genetic Predisposition to Disease / genetics
  • Genome-Wide Association Study
  • High-Throughput Screening Assays
  • Humans
  • Inflammatory Bowel Diseases / etiology
  • Inflammatory Bowel Diseases / genetics*
  • Inflammatory Bowel Diseases / metabolism
  • Metabolome
  • Metabolomics* / methods
  • Prognosis
  • Proteomics* / methods